Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
Provided By GlobeNewswire
Last update: May 14, 2025
Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101
Read more at globenewswire.comNASDAQ:BEAM (8/6/2025, 3:31:50 PM)
18.4025
-0.3 (-1.59%)
Find more stocks in the Stock Screener
